{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:39:35Z","timestamp":1783629575897,"version":"3.55.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008572","name":"University of Ottawa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008572","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019688","name":"Department of Medicine, Georgetown University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.thromres.2023.04.015","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T12:04:18Z","timestamp":1682510658000},"page":"82-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial"],"prefix":"10.1016","volume":"226","author":[{"given":"Nicola","family":"Potere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Di Nisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Porreca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Tagalakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Shivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Delluc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjeeta","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil S.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.thromres.2023.04.015_bb0005","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.thromres.2023.04.015_bb0010","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2023.04.015_bb0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.thromres.2016.06.012","article-title":"Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: the longitudinal investigation of thromboembolism etiology","volume":"144","author":"Cushman","year":"2016","journal-title":"Thromb. Res."},{"issue":"12","key":"10.1016\/j.thromres.2023.04.015_bb0020","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood.2019003528","article-title":"How I treat obese patients with oral anticoagulants","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2023.04.015_bb0025","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2023.04.015_bb0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.thromres.2021.10.009","article-title":"Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: drug levels and clinical outcomes","volume":"208","author":"Ballerie","year":"2021","journal-title":"Thromb. Res."},{"issue":"11","key":"10.1016\/j.thromres.2023.04.015_bb0035","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.008005","article-title":"Anticoagulation treatment and outcomes of venous thromboembolism by weight and body mass index: insights from the Veterans Health Administration","volume":"14","author":"Perino","year":"2021","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"issue":"2","key":"10.1016\/j.thromres.2023.04.015_bb0040","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11239-022-02668-8","article-title":"Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism","volume":"54","author":"Novak","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"issue":"5","key":"10.1016\/j.thromres.2023.04.015_bb0045","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1055\/a-1588-9155","article-title":"Oral anticoagulant use in patients with morbid obesity: a systematic review and meta-analysis","volume":"122","author":"Wang","year":"2022","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2023.04.015_bb0050","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.thromres.2023.04.015_bb0055","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.thromres.2023.04.015_bb0060","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J. Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482300107X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482300107X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:50:53Z","timestamp":1758736253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004938482300107X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":12,"alternative-id":["S004938482300107X"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2023.04.015","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2023.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}